Navigation Links
Vandetanib in thyroid cancer: No proof of added benefit
Date:11/9/2012

Vandetanib (trade name Caprelsa) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, because no data on patient-relevant outcomes for those patients for whom the drug is approved were presented by the drug manufacturer in its dossier. In view of these deficiencies, IQWiG considered itself compelled to declare the contents of the dossier as "incomplete".

"Best supportive care" as the appropriate comparator therapy

As specified by the Federal Joint Committee (G-BA), vandetanib should be compared with "best supportive care". This means the best possible supportive therapy, optimized for the individual patient for alleviation of symptoms and improvement in the quality of life.

The only study relevant for this benefit assessment compared the administration of vandetanib in combination with "best supportive care" with a treatment consisting of "best supportive care" alone.

Study population differs from approval population

Vandetanib is approved for patients with an "aggressive and symptomatic" medullary thyroid cancer (MTC) in whom surgery is no longer possible, the cancer is already very large or from which secondaries (metastases) have already formed in other regions of the body. The European regulatory authority - the European Medicines Agency (EMA) - had restricted the therapeutic indication in such a way in order to produce an overall positive benefit-risk balance. This is because treatment with vandetanib also involves major risks and can, for example, lead to severe heart rhythm disturbances.

However, in the study presented by the manufacturer, patients in whom the course of the disease was not "aggressive and symptomatic" were also enrolled. This applied to a total of about 44% of the study participants. This means that the study population - in contrast to the statements made by the manufacturer - was much wider than just the approval population. A benefit assessment pursuant to AMNOG should, however, only be undertaken for patients for whom the drug is actually approved. But the analysis of the study presented by the manufacturer did not allow for this.

Separate analysis would have been possible

The pharmaceutical company did not provide a separate analysis of the data with regard to patient-relevant outcomes (mortality, morbidity, quality of life) for patients treated in accordance with the approval status. However, comments of the EMA from the approval process prove that this group of patients is clearly distinguishable within the study and therefore the company could have presented a separate analysis for the benefit assessment.

The incompleteness of the dossier does not allow a reliable assessment of the new drug. An added benefit of vandetanib compared with "best supportive care" is therefore not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure, which provides further information and can result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>
Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
0049-221-356-856
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Thyroid Condition Linked to Heart Problems: Study
2. Lower-Dose Radioiodine Effective Against Thyroid Cancer
3. Staging and risk stratification of thyroid cancer improved with SPECT/CT
4. Obese More Likely to Be Diagnosed With Advanced Thyroid Cancer
5. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
6. Hyperthyroidism linked to increased risk of hospitalization for heart and blood-vessel disease
7. Gene expression test identifies low-risk thyroid nodules
8. Detecting thyroid disease by computer
9. Experts issue recommendations for treating thyroid dysfunction during and after pregnancy
10. Drug May Aid People With Advanced Thyroid Cancer
11. Thyroid Treatment Guidelines for Pregnant Women Revised
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: